HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $4.24 million. The enterprise value is $10.06 million.
| Market Cap | 4.24M |
| Enterprise Value | 10.06M |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 1.84 million shares outstanding. The number of shares has increased by 285.74% in one year.
| Current Share Class | 1.84M |
| Shares Outstanding | 1.84M |
| Shares Change (YoY) | +285.74% |
| Shares Change (QoQ) | +46.85% |
| Owned by Insiders (%) | 10.16% |
| Owned by Institutions (%) | 8.94% |
| Float | 1.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| Forward PS | n/a |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 0.88.
| Current Ratio | 0.06 |
| Quick Ratio | 0.04 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.26 |
Financial Efficiency
Return on equity (ROE) is -151.36% and return on invested capital (ROIC) is -37.30%.
| Return on Equity (ROE) | -151.36% |
| Return on Assets (ROA) | -13.88% |
| Return on Invested Capital (ROIC) | -37.30% |
| Return on Capital Employed (ROCE) | -76.16% |
| Weighted Average Cost of Capital (WACC) | 10.79% |
| Revenue Per Employee | $192,034 |
| Profits Per Employee | -$611,719 |
| Employee Count | 35 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HCW Biologics has paid $330,186 in taxes.
| Income Tax | 330,186 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.84% in the last 52 weeks. The beta is 2.36, so HCW Biologics's price volatility has been higher than the market average.
| Beta (5Y) | 2.36 |
| 52-Week Price Change | -88.84% |
| 50-Day Moving Average | 4.14 |
| 200-Day Moving Average | 6.41 |
| Relative Strength Index (RSI) | 33.51 |
| Average Volume (20 Days) | 146,109 |
Short Selling Information
The latest short interest is 20,979, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 20,979 |
| Short Previous Month | 29,960 |
| Short % of Shares Out | 1.14% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 0.33 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $6.72 million and -$21.41 million in losses. Loss per share was -$27.18.
| Revenue | 6.72M |
| Gross Profit | 6.45M |
| Operating Income | -6.18M |
| Pretax Income | -5.25M |
| Net Income | -21.41M |
| EBITDA | -5.58M |
| EBIT | -6.18M |
| Loss Per Share | -$27.18 |
Balance Sheet
The company has $741,324 in cash and $6.56 million in debt, with a net cash position of -$5.82 million or -$3.17 per share.
| Cash & Cash Equivalents | 741,324 |
| Total Debt | 6.56M |
| Net Cash | -5.82M |
| Net Cash Per Share | -$3.17 |
| Equity (Book Value) | 7.43M |
| Book Value Per Share | 4.59 |
| Working Capital | -17.51M |
Cash Flow
| Operating Cash Flow | -11.45M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 614,943 |
| Net Borrowing | -204,466 |
| Free Cash Flow | -11.45M |
| FCF Per Share | -$6.24 |
Margins
Gross margin is 95.91%, with operating and profit margins of -92.02% and -83.05%.
| Gross Margin | 95.91% |
| Operating Margin | -92.02% |
| Pretax Margin | -78.14% |
| Profit Margin | -83.05% |
| EBITDA Margin | -83.09% |
| EBIT Margin | -92.02% |
| FCF Margin | n/a |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -285.74% |
| Shareholder Yield | -285.74% |
| Earnings Yield | -504.73% |
| FCF Yield | -270.00% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 30, 2026. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
HCW Biologics has an Altman Z-Score of -6.87 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.87 |
| Piotroski F-Score | 3 |